Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera Sciencesâ management team are dedicated and focused to making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive commercialization and development of ophthalmic products. Source
No articles found.
GuruMD directs patients away from costly emergency rooms and urgent cares by provi...
GuruMD directs patients away from costly emerge...
PhaseBio is a clinical-stage biopharmaceutical company focused on the development ...
PhaseBio is a clinical-stage biopharmaceutical ...
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ...
Bellicum Pharmaceuticals is a clinical-stage bi...
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
NeurMedix, Inc., is a clinical-stage biotechnology company that engages in develop...
NeurMedix, Inc., is a clinical-stage biotechnol...
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...
Aerie Pharmaceuticals is an ophthalmic pharmace...
Join the National Investor Network and get the latest information with your interests in mind.